Skip to main content

ADVERTISEMENT

loperamide

Research in Review
01/11/2017
JCP Editors
Loperamide plus budesonide reduces the rate of toxic effects associated with neratinib for patients with human epidermal growth factor receptor-2 positive (HER2+) breast cancer, according to the results of a trial...
Loperamide plus budesonide reduces the rate of toxic effects associated with neratinib for patients with human epidermal growth factor receptor-2 positive (HER2+) breast cancer, according to the results of a trial...
...
01/11/2017
Journal of Clinical Pathways